New trial evaluating treatment designed to lower the risk of cancer returning
Dr. Edward Garon’s Novartis CACZ885T2301 study is now open to enrollment at select TRIO- US sties. This is a randomized phase 3 study evaluating the efficacy and safety of the immunotherapy drug canakinumab versus placebo as adjuvant therapy in patients with stage II-IIIA and IIIB completely resected non-small cell lung cancer (NSCLC). Adjuvant therapy refers to an anti-cancer treatment given after surgery in order to lower the risk of the cancer coming back. Patients may have received adjuvant chemotherapy with or without radiation prior to enroll- ment. This study is expected to open soon at UCLA Main Campus and is currently open at TRIO -US sites in: Bakersfield, CA; Ft. Wayne, IN; Fullerton, CA; Santa Maria, CA; and Wichita, KS.
Combination therapy study at UCLA Main Campus
Dr. Jonathan Goldman’s Vaccinex VX15-2503-04 study is now open to enrollment. This is a phase 1B/2 dose escalation and dose expansion study of a drug called VX15-2503 in combination with the immunotherapy drug avelumab. In order to enroll, patients must have been diagnosed with stage III-IV NSCLC and must test negative for EGFR, ALK, and ROS1 mutations. Subjects must not have received prior immunotherapy for their cancer. Patients must have either experienced progression of their cancer on or declined treatment with cytotoxic chemotherapy, and must not have received greater than three different regimens of prior systemic anti- cancer therapy. This study is currently open to enrollment at UCLA Main Campus.
Trial open for patients with advanced NSCLC that is not amenable to curative therapy
Dr. Aaron Lisberg’s Daiichi Sankyo DS1062-A-J101 study is now open to enrollment. This is a phase 1, first-in-human dose escalation and dose expansion study of a drug called DS1062a. The purpose of a dose escalation and dose expansion study is to determine the dose of a drug that is safe for humans. In order to enroll in this study, patients must have been diagnosed with advanced NSCLC that is not amenable to curative therapy. Patients who are enrolled in the study may continue to receive DS1062a until withdrawal of consent, progressive disease, or unacceptable toxicity. This study is open to accrual at UCLA Main Campus.